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Background: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that
microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to
clinical evolution. Future efforts need to be directed towards microperfusion monitoring and treatment. This study
explored the utility of thenar muscle oxygen saturation (StO2) and its changes during a transient vascular occlusion
test (VOT) to measure the microcirculatory response to drotrecogin alfa (activated) (DrotAA) in septic patients.
Methods: A prospective, observational study was performed in three general intensive care units at three university
hospitals. We studied 58 patients with recent onset of severe sepsis or septic shock and at least two organ
dysfunctions. Thirty-two patients were treated with DrotAA and 26 were not treated because of formal
contraindication. StO2 was monitored using near-infrared spectroscopy (NIRS), and VOT was performed to obtain
deoxygenation (DeOx) and reoxygenation (ReOx) slopes. Measurements were obtained before DrotAA was started
and were repeated daily for a 96-hour period.
Results: Patients’ characteristics, outcome, severity, and baseline values of StO2, DeOx, and ReOx did not differ
between groups. Treated patients significantly improved DeOx and ReOx values over time, whereas control patients
did not. In treated patients, ReOx improvements were correlated to norepinephrine dose reductions. Early clinical
response (SOFA improvement after 48 hours of treatment) was not associated to changes in VOT-derived slopes. In
the treated group, the relative improvement of DeOx within 48 hours was able to predict mortality (AUC 0.91,
p < 0.01).
Conclusions: In patients with severe sepsis or septic shock, DrotAA infusion was associated with improvement in
regional tissue oxygenation. The degree of DeOx amelioration after 2 days in treated patients predicted mortality
with high sensitivity and specificity. Thus, StO2 derived variables might be useful to evaluate the microcirculatory
response to treatment of septic shock.
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Sepsis is a leading cause of death in critically ill patients
despite the use of modern antibiotics and resuscitation
strategies [1]. In recent years, the introduction of early
goal-directed therapy (EGDT) has improved outcome of se-
vere sepsis and septic shock [2,3]. EGDT interventions seek
the normalization of global markers of hypoperfusion, such
as lactate and venous oxygen saturations (central or mixed).
However, sepsis is a complex syndrome that affects the
microcirculation and tissue microperfusion. There is in-
creasing evidence that persistent microcirculatory alter-
ations are related to clinical evolution independently from
macrohemodynamic improvement [4-8]. Increased micro-
vascular heterogeneity during sepsis mediated by the pres-
ence in varying degrees of stopped-flow capillaries, cell
aggregation and thrombosis phenomena, vasoconstriction,
and alteration of red cell flexibility among others [9] might
be only partially reversed by macrohemodynamics resusci-
tation strategies. This strengthens the opinion that future
research efforts need to be directed towards monitoring
technologies and therapies targeting tissue microperfusion.
Near-infrared spectroscopy (NIRS) technology mea-
sures tissue hemoglobin oxygen saturation (StO2) in a
tissue sample volume containing the three vascular com-
partments (arterial, capillary, and venous). Tissue perfu-
sion impairment increases O2 extraction, and thus, it
decreases venous O2 saturation, resulting in lower StO2
values. In clinical scenarios, StO2 has been associated
with patients’ alterations in peripheral circulation [10],
as well as in healthy volunteers [11], it has shown its
ability to predict noninvasively the presence of global tis-
sue hypoxia [12-14] and has demonstrated prognostic
utility [15,16]. For instance, persistent low StO2 values
have been related to worse organ failure evolution either
in septic shock [16] or hemorrhagic shock [15]. Thus,
improvement in tissue perfusion might be reflected by
StO2 monitoring. A dynamic functional test consisting
in a transient vascular occlusion (VOT) seems to im-
prove the assessment of the microperfusion. According
to the StO2 response to ischemia and reperfusion, StO2
deoxygenation (DeOx) and reoxygenation (ReOx) rates
are obtained. Local tissue O2 consumption can be evalu-
ated by analyzing the DeOx slope during the period of
ischemia, and the ReOx following cuff-release reflects
the ability of the tissue to recruit oxygenated blood vol-
ume, depending on both endothelial integrity and perfu-
sion pressure. Importantly, VOT-derived variables have
been independently associated to peripheral circulation
derangements [10], and both, DeOx and ReOx have
shown their prognostic value consistently in septic con-
ditions [17-22].
Effect of DrotAA infusion of the microcirculatory al-
terations has been evaluated either using direct measures
of microperfusion, such as video-microscopy, or usingtissue oxygenation measurements, such as StO2-derived
variables [23,24]. Because StO2-derived parameters have
been proven useful to detect the DrotAA effects on
microperfusion [24], we hypothesized that differences in
StO2-derived parameters evolution might reflect differ-
ences in microperfusion among patients whose microcir-
culation responds to DrotAA and those that do not
respond. In that case, StO2 monitoring might be useful
to guide therapy.
Methods
The study was designed as a prospective, observational
research in three intensive care units (ICU). The three
ICUs were from Hôpital de Bicêtre and Hôpital
Lariboisière in France and Hospital de Sabadell in Spain.
The Ethical Review Board of each participating center
approved the study, and oral or written informed con-
sent was obtained from the patient or next of kin
according to the local review board’s requirement.
Patients
Patients were recruited according to the following inclu-
sion criteria: age >18 years old, with proven or suspected
infection; infection was suspected when white blood
cells were present in a normally sterile body fluid, or a
viscera was perforated, or purulent sputum production
was present associated with chest x-ray consistent with
pneumonia, or a clinical syndrome of inflammation was
associated with a high probability of infection, such as
purpura fulminans or ascending cholangitis; presence of
severe sepsis [25], with at least two sepsis-associated
organ failures, newly developed (within the 24 hours be-
fore enrollment), and not explained by an underlying
disease or by the effects of concomitant therapy.
Among the patients who met inclusion criteria two
groups were defined: the treated group who received
DrotAA and the control group, which did not receive
this therapy because of formal contraindication. Formal
contraindication to receive DrotAA was considered
when one or more of the following criteria were present:
platelet count <30,000/mm3, active bleeding or increased
risk of bleeding, need for therapeutic heparin, warfarin,
or other anticoagulants, antiplatelets or glycoprotein IIb/
IIIa receptor antagonists, thrombolytic therapy, anti-
thrombin, or recombinant factor VIIa therapy.
Exclusion criteria
Patients were excluded: when they declined to give their
written, informed consent; those who have a body
weight <30 kg or >135 kg; a documented multiple organ
dysfunction for more than 24 hours before inclusion; a
delay >36 hours before the start of DrotAA for the first
organ dysfunction; died or being moribund (within 24
hours); HIV/AIDS and known end-stage processes;
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ment; pregnant or lactating women; trauma in both
upper limbs, or haematoma or skin lesions in the thenar
eminence that could hinder placement of the NIRS sen-
sor probe.
During data acquisition, no new concomitant medica-
tions were prescribed. Standard treatment was applied
following local clinical protocols according to the Sur-
viving Sepsis Campaign recommendations [3]. Patients
in the treated group received a continuous infusion of
DrotAA (24 μg/kg/hour) for 96 hours.
Measurements
Patient demographics, diagnosis at ICU admission, focus
of sepsis, and Acute Physiology and Chronic Health
Evaluation II (APACHE II) and Simplified Acute Physi-
ology Score II (SAPS II) scores were recorded at
inclusion.
Thenar oxygen saturation (StO2)
Thenar StO2 was measured using an InSpectra™ StO2
Monitor model 650 or model 325 (Hutchinson Technol-
ogy Inc; Hutchinson, MN) with a 15-mm probe,
according to device availability at each site. The probe
was placed on the thenar eminence, on intact skin, and
never adjacent to an arterial line.
The VOT was performed using a pneumatic cuff tour-
niquet placed around the forearm, proximal to the StO2
probe, as previously described [26]. Patients remained in
a semirecumbent position, with their arms straight on
the bed. The cuff-pressure was raised quickly (3–5 sec-
onds) up to 40 mmHg above systolic blood pressure.
According to local VOT protocol, vascular occlusion
was stopped either once the StO2 value dropped to 40%
or after 3 minutes of ischemia. Once the cuff was de-
flated, StO2 was recorded until its value remained stable
again.
Baseline steady-state StO2, DeOx, and ReOx were
automatically computed using the InSpectra Analysis
Software provided by Hutchinson Technology Inc.
Follow-up
The following data were obtained and recorded at inclu-
sion (T0) and every 24 hours up to 96 hours, obtaining
five sets of measurements (T0, T24, T48, T72, and T96):
 NIRS-derived variables: StO2, DeOx, and ReOx.
 Hemodynamic, respiratory, and blood sample
parameters: arterial blood pressure, heart rate,
vasoactive drug doses, pulse-oximeter oxygen
saturation (SpO2), ventilator settings if intubated,
arterial and central venous blood gases and acid–
base status, lactate, hemoglobin, and axillary
temperature. Sequential Organ Failure Assessment (SOFA) score.
In order to analyze the early clinical response of the
DrotAA group, patients whose SOFA score decreased
≥25% at T48 were classified as early SOFA-responders.
Mortality at day 28 and ICU length of stay also were
recorded.
Statistical analysis
Data were analyzed using PASW version 18 (IBM–SPSS;
Chicago, IL). Descriptive statistics were computed for all
the studied variables. Continuous variables were
expressed as mean ± SD, and categorical variables were
reported as proportions (%). We used two-tailed
Pearson’s chi-square tests to compare categorical vari-
ables between groups and two-tailed Mann–Whitney U
tests to compare continuous variables. Wilcoxon test for
repeated measurements was used to evaluate the time
course of the StO2 variables. Spearman’s rho test was
used to evaluate the correlation among NIRS-derived
variables with SOFA, mean arterial pressure (MAP), and
norepinephrine (NE) dose evolution. Receiver operating
characteristic test (ROC curve) was performed to
analyze predictive potential of NIRS-derived variables.
All statistics were two-tailed, and p < 0.05 was consid-
ered to be significant.
Results
A total of 58 patients with severe sepsis or septic shock
were included: 32 patients treated with DrotAA (treated
group), and 26 patients who did not receive DrotAA
(control group). The main clinical characteristics and
outcomes for each group of patients are shown in
Table 1. Treated patients were younger than control pa-
tients (63 ± 15 vs. 73 ± 12 years, p < 0.02) and received
higher baseline NE doses (0.8 ± 1.0 μg/kg/min vs. 0.4 ±
0.3 μg/kg/min, p = 0.03). No differences in other base-
line hemodynamic, respiratory, metabolic, and tissue
hemoglobin saturation parameters were found between
the two groups.
Hemodynamics and organ failure evolution
Treated patients significantly increased their MAP after
48 hours of treatment, whereas in control patients MAP
only improved at T96 (Figure 1). NE infusion evolution
also was different in both groups. The treated group
showed a significant decrease in NE infusion rate at each
time point of the study, whereas the control group
showed a significant increase in NE requirements at
T24, with progressive reduction of NE doses starting at
T48 (Figure 1).
The evolution of organ failure assessed by SOFA score
was similar between groups: 34% of patients were con-
sidered to be early SOFA-responders in the treated
Table 1 Clinical characteristics of the studied patients
Treated (n = 32) Controls (n = 26) p
Gender (male %) 63% 50% 0.3





Skin/soft tissue 10% 23%
Urinary tract 0% 4%
SAPS II 56 ± 13 59 ± 11 0.4
APACHE II 25 ± 6 24 ± 7 0.6
SOFA score at inclusion 11 ± 3 11 ± 2 0.4
Value at inclusion Mean arterial pressure (mmHg) 77 ± 9 75 ± 11 0.6
Norepinephrine dose (mcg/kg/min) 0.8 ± 1.0 0.4 ± 0.33 0.04
Heart rate (bpm) 94 ± 20 96 ± 22 0.7
Lactate (mmol/L) 3.5 ± 2.0 4.0 ± 3.5 0.6
pH 7.30 ± 0.11 7.31 ± 0.12 0.8
Base deficit (mmol/L) −9.0 ± 4.3 −7.5 ± 7.2 0.4
ScvO2 (%) 70 ± 10 71 ± 13 0.8
SpO2 (%) 96 ± 4 98 ± 3 0.2
PaO2/FiO2 181 ± 102 255 ± 164 0.3
Hb (g/dL) 11.2 ± 2.0 10.9 ± 2.2 0.6
StO2 (%) 80 ± 8 78 ± 12 0.5
Deoxygenation slope (%/min) −16.2 ± 18 −17.4 ± 14.4 0.4
Reoxygenation slope (%/s) 3.2 ± 2.6 2.3 ± 1.8 0.1
Mortality (n, %) 6 (19) 10 (38) 0.09
Length of ICU stay (days) 26 ± 21 19 ± 17 0.2
Clinical characteristics at inclusion according to treatment group. Continuous variables are expressed as mean ± SD. Categorical variables are expressed as
proportions (%). Two-tailed significance is shown under “p” column.
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SOFA score at each time point of the study were found
between treated and control patients. However, treated
patients showed significantly earlier SOFA decrease at
T72 and T96 (p < 0.01 in both cases), whereas in control
patients SOFA decreased significantly only at T96
(p < 0.01). Overall, mortality rate was 28% (19% in the
treated group and 38% in the control group, p = 0.09).
StO2 evolution: treated vs. control
Absolute steady-state StO2 did not change over time,
and no differences in its evolution were observed when
comparing treated and control groups. In the treated
group, DeOx and ReOx values improved significantly
and consistently over time, at each time point of the
study. This evolution was not observed in control pa-
tients, in whom DeOx remained unchanged (Figure 2A),
and ReOx only increased at T48 (Figure 2B). Relative
improvement in DeOx over time was not correlated torelative changes in MAP or NE use over time in both
groups. However, in treated patients, changes in ReOx
over time were inversely correlated to relative changes
in NE dosage over time (r = −0.5, p < 0.01 at T24;
r = −0.5, p < 0.02 at T48) but not to MAP changes. This
association was not observed in the control group.
DrotAA patients: organ failure evolution and mortality
When analyzing treated patients, similar patterns in
StO2-variables evolution were observed according to
organ failure evolution. Clinical responders and nonre-
sponders at T48 (SOFA48 5 ± 1 responders vs. 12 ± 3
nonresponders, p < 0.01) showed no significant differ-
ences in StO2, DeOx, and ReOx evolution compared
with nonresponders (Figure 3). However, DeOx and
ReOx evolution significantly differed when comparing
patients according to 28-day mortality (Figure 4). Both
DeOx and ReOx significantly improved over time in pa-
tients who survived, whereas no time-related change was
Figure 1 Evolution over time in treated and control patients. *p < 0.05 compared with T0;
§p < 0.05 compared with control patients.
Figure 2 StO2-derived variables evolution: treated vs control
group. A. DeOx evolution in treated and control patients. Mean and
SE are represented. *p < 0.05 compared with T0;
§p < 0.05 compared
with control patients. B. ReOx evolution in treated and control
patients. Mean and SE are represented. *p < 0.05 compared with T0;
§p < 0.05 compared with control patients.
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ment in DeOx, measured as the ratio between DeOx48
and DeOx0, was the best parameter for 28-day mortality
prediction, with an AUC of 0.91 (p < 0.01).
Discussion
In the present study, we sought to confirm the capacity
of StO2-derived variables during DrotAA infusion to as-
sess the response of the microcirculation to this treat-
ment. We analyzed whether the evolution of these
variables would predict clinical evolution and outcome.
Because absolute steady-state StO2 has consistently re-
vealed poor sensitivity to detect regional hypoperfusion
in septic patients [12,22,27], we did not expect to find
any differences in this parameter between treated and
control patients, neither between early SOFA-responders
and SOFA-nonresponders in the treated group. Indeed,
our data support the lack of sensitivity of this parameter
when measured on the thenar eminence.
In our population, we confirmed a different evolution
of VOT-derived variables associated to DrotAA therapy.
Previous observations [24] are corroborated in our mul-
ticenter cohort, with the detection of progressive local
oxygen consumption improvements, as suggested by the
DeOx response, associated to DrotAA therapy.
ReOx improvements also have been found. Consider-
ing the simultaneous evolution patterns of MAP, NE re-
quirements, and ReOx improvement, it might suggest
that the DrotAA group displayed an earlier recovery of
the vascular endothelial function compared with control
patients. Regrettably, despite both groups were managed
Figure 3 None of the VOT-derived variables was associated with early SOFA improvement. Mean and SE are represented. *p < 0.05
compared with T0.
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ventions that might affect the microcirculation were not
computed (such as red blood cell transfusion), we can-
not attribute this improvement to DrotAA therapy.
Nevertheless, ReOx improvements may account for the
significant reductions observed in NE requirements to
maintain similar or even higher MAP levels. Therefore,
our results suggest that ReOx would be able to reflect
endothelial integrity improvement, as its increases
matched NE reductions.
Many studies have underscored the prognostic impli-
cations of either DeOx or ReOx [16-22]. In our data,
DeOx evolution was not associated to early clinicalimprovement, as measured by SOFA changes at T48.
However, in our treated population, the degree of im-
provement in DeOx was directly associated with sur-
vival, whereas in control patients DeOx response did not
change over time nor was associated to outcome. The
interpretation of these differences of association is com-
plex: our first elucidation would be that although we
were unable to detect early recovery of organ failure,
being able to recruit the microcirculation might have
impact on survival. First, although microcirculatory im-
pairment might be the initial fundamental condition for
organ dysfunction development, organ recovery might
not parallel microcirculatory changes. Other conditions,
Figure 4 StO2-derived variables evolution and outcome. A.
DeOx evolution according to mortality. Mean and SE are
represented. *p < 0.05 compared with T0;
§p < 0.05 compared with
nonsurvivors. B. ReOx evolution according to mortality. Mean and SE
are represented. *p < 0.05 compared with T0;
§p < 0.05 compared
with nonsurvivors.
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portant role in the recuperation of cellular function. Sec-
ond, we also need to take into account the potential
limitations of the score used for organ dysfunction
measurement. It seems obvious that SOFA score might
not be sensitive enough to detect slight variations in
organ function. Finally, the fact that these associations
were not present in the control group also could also
mean that DeOx variation is just an associated
phenomenon to DrotAA therapy that does not change
clinical evolution.
In our population, despite ReOx significantly improved
over time in the treatment group, the magnitude of
ReOx augmentation was not associated with clinical evo-
lution or mortality. Since both, endothelial integrity and
tissue perfusion pressure might account for the final ob-
served ReOx value [22,28], the interpretation of this
variable appears complex. Although ReOx has demon-
strated its predictive value in many studies, it seems to
be subjected to several factors that could act as
confounding factors, which might limit its use for ther-
apy guidance purposes.
Taking into account these contradictory results, the
fact that DrotAA patients clearly improved regional oxy-
genation, as previously shown by others [23,24], but
DrootAA has failed repeatedly to prove effectiveness on
prognosis [29,30], lead us to the next questions: Aremicrocirculation-targeted therapies futile? Despite our
results support the DrotAA effect on regional tissue per-
fusion, the degree of regional improvement derived from
this therapy might not be associated to better prognosis.
Furthermore, similar StO2 evolution patterns have been
noticed for all treated patients, regardless of their clinical
evolution. Furthermore, initial StO2 parameters were not
able to predict StO2 response to therapy, and thus, it
could not have been used to decide whether to treat, fur-
ther limiting the use of StO2 in the decision tree. Finally,
it should be considered that the observed results might
be an epiphenomena with no clinical implications. Fur-
ther studies are needed to clarify those points, as the
present study has several limitations that prevent this
question to be elucidated.
Study limitations
A major limitation, that restrains the interest of the re-
sults, is that it provides data about a therapy that is no
longer available due to its lack of proven effectiveness.
Although StO2 derived variables have demonstrated
their ability to detect the effects of DrotAA on microcir-
culation, it has not been proven that these changes have
repercussion on outcome. Nevertheless, these results are
interesting as they prove the utility of a noninvasive
monitoring system to follow microcirculation response
to a given therapy and opens new opportunities to study
the effects new therapies on microcirculation of other
therapies, the impact of microcirculation amelioration
on outcome, and to develop treatment tailoring strat-
egies, not possible until now due to a lack of available
method to evaluate individual response easily.
The second major limitation is that although prospect-
ive and multicentric, this study has some important is-
sues to take into account. First, the treated and control
group differed for some clinical characteristics; age and
intensity of cardiovascular support. Second, the observa-
tional nature of the study implied that the control group
consisted in patients with contraindications for DrotAA
therapy, which might differ from a real matched control
group. We cannot exclude that the different age or pre-
vious pathologies that contraindicated DrotAA therapy
could explain some of the observed differences. Never-
theless, the severity scores were similar and the dose of
norepinephrine required for maintaining the targeted
MAP at the time of inclusion was even higher in the
treated group, suggesting that the patients of the treated
group were not less sick than the patients of the control
group. Third, the impact of other supportive therapies,
such as fluid resuscitation or blood transfusion on StO2
and clinical evolution, was not analyzed. Although the
participating centers followed the Surviving Sepsis Cam-
paign guidelines, differences in administered therapies
might have occurred. Fluid resuscitation is one major
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has direct impact on microcirculation. The guidelines re-
mark the importance of early fluid administration, but
the timespan of the present study goes farther than the
early phase. Because many global hemodynamic parame-
ters are used for fluid-administration guidance, and the
microcirculation has shown repeatedly its uncoupling
from macrocirculation within the time-course of sepsis
[31,32], it is difficult to interpret the relationship
between appropriate fluid resuscitation and microcircu-
lation. The definition of “appropriate” fluid administra-
tion, both in early and late phase of sepsis management,
is not an easy task, and we are still far from integrating
macro- and microcirculation for evaluation of fluid
optimization purposes.
Hence, tissue oxygenation improvement cannot be
solely attributed to DrotAA therapy. However, our re-
sults emphasize that StO2-derived parameters might be
clinically useful to evaluate microcirculation response to
drugs or interventions in sepsis.
Finally, two different VOT protocols have been used,
as StO2 monitoring was performed using the local
protocol of each center. Fifty percent of treated patients
and all control patients were evaluated using a time-
guided protocol. Although the use of time-guided (3 mi-
nutes of occlusion) or StO2-guided (reaching an
ischemic StO2-threshold of 40%) VOT protocol has no
influence on StO2, or DeOx values, it may affect the
ReOx response, as stated by some authors [33-35].
Therefore, there might be slight differences in ReOx
among patients derived from the ischemic challenge
methodology used. However, the fact that only 15% of
the studied patients using time-guided VOT did not
reach the StO2 ischemic threshold within 3 minutes, and
that the evolution of StO2 parameters were analyzed
using the same VOT protocol in each patient, minimized
the impact of this methodological limitation.
Conclusions
In a population of patients with severe sepsis or septic
shock, DrotAA infusion was associated with improved
regional tissue oxygenation over time, as quantified by
DeOx and ReOx. The relative improvement in DeOx
after 2 days of therapy predicted mortality with high sen-
sitivity and specificity.
Although our results cannot establish a causality
relationship between DrotAA infusion and tissue oxy-
genation improvement, they reinforce the fact that
StO2-derived parameters might be useful to monitor the
impact of therapy on the microcirculation, as well as to
predict outcome. Assessment of microperfusion state
and evolution in response to therapies targeting micro-
circulation should be evaluated further as a way to
develop better and more individualized therapies.Abbreviations
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